Date:9/17/2009

====== ====== * Marketable securities $1,792 $4,495 ===== ===== Pharmacyclics, Inc. (a development stage enterprise) Reconciliation of selected GAAP measures to non-GAAP measures Fiscal Fourth Quarter 2009 (unaudited) (in thousands) Three Months Ended June 30 2009 Reconciliation of selected GAAP measures to non-GAAP measures (1) Fiscal Q4 Fiscal Q4 2009 2008 ------- ------- NET LOSS per GAAP ($5,406) ($4,628) ------- ------- Adjustments R&D share-based compensation (2) 186 210 G&A share-based compensation (2) 186 248 Interest Adjustment for RWD loan (3) 299 - Provision for Income Tax (4) 550 - ------ ------ 1,221 458 ------- ------- NET LOSS per non-GAAP ($4,185) ($4,170) ------- ------- (1) This presentation includes non-GAAP measures. Our non-GAAP measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read only in conjunction with our consolidated financial statements prepared in accordance with GAAP. See also "Use of non-GAAP Financial Measures" in this press release. (2) All share-based compensation was excluded from the non-GAAP Analysis. (3) Due to the below
'/>"/>

SOURCE Pharmacyclics Copyright©2009 PR Newswire. All rights reserved

1 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
Related medicine news :

1. Pharmacyclics Sets Record Date for Rights Offering
2. Pharmacyclics Reports Third Quarter Fiscal 2009 Financial Results
3. Pharmacyclics Announces Dr. Ahmed Hamdy as New Chief Medical Officer
4. Pharmacyclics Receives Nasdaq Notification
5. Pharmacyclics Files Schedule 14D-9 Statement with Securities and Exchange Commission
6. Pharmacyclics Reports Third Quarter 2008 Financial Results
7. Pharmacyclics Announces Conference Call to Discuss Third Quarter 2008 Financial Results
8. Pharmacyclics Announces Conference Call to Discuss Second Quarter 2008 Financial Results
9. Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases
10. J.D. Power and Associates Reports: Among Pharmacy Customers, Satisfaction is Equally as High for the Privately Insured and for Those With Public-Private Insurance
11. Somanetics Reports Financial Results for the Third Quarter of Fiscal 2009